Sepranolone

The endogenous 3beta-epimer of allopregnanolone that selectively blocks allopregnanolone at the GABA-A receptor; a first-in-class GAMSA in Phase 2 for PMDD.

Across Phase 1 and Phase 2 work isoallopregnanolone has shown a favourable tolerability profile, with adverse events largely confined to mild injection-site reactions related to its subcutaneous route. Because it is an endogenous molecule that antagonises only the allopregnanolone-driven component of GABA-A signalling and spares basal GABA, benzodiazepine, and barbiturate responses, it has not produced the sedation, cognitive blunting, motor impairment, or withdrawal seen with benzodiazepines and other broad GABA-A modulators; pharmacodynamic studies in healthy women found no impairment of saccadic eye velocity or sedation attributable to the compound itself (Hedstrom 2009).

Its mechanism is fundamentally corrective rather than suppressive, aiming to normalise an exaggerated neurosteroid response rather than to depress the system globally. Long-term safety data remain limited, and as an unapproved investigational agent it should not be regarded as an established or self-administered treatment.

Isoallopregnanolone was long known to steroid chemists as an epimeric metabolite of progesterone before its distinctive pharmacology was recognised. The pivotal insight came from Torbjorn Backstrom and colleagues at Umea University in Sweden, who during the early 2000s demonstrated that this 3beta-epimer, rather than being inert, actively opposed allopregnanolone: Lundgren and coworkers showed in 2003 that it inhibits allopregnanolone-stimulated chloride flux, and Backstrom's group showed in 2005 that it antagonises the anaesthetic effect of allopregnanolone in male rats. This reframed the paradoxical, negative-mood effects of progesterone metabolites seen in premenstrual disorders as a GABA-A phenomenon that could be pharmacologically reversed.

The compound was advanced into clinical development as UC1010 and later branded Sepranolone by the Swedish company Asarina Pharma. A proof-of-concept Phase 2 study in PMDD reported by Bixo and colleagues in 2017 was followed by a larger randomised, double-blind trial published in 2021 (Backstrom 2021). Beyond PMDD the molecule has been explored for menstrually related and compulsive conditions, including tic disorders and Tourette syndrome, where it reduced tic-like behaviour in the D1CT-7 mouse model (Cadeddu 2020), and for estrus-cycle-dependent aggression in animals (Backstrom 2023).

Within neuroendocrinology and reproductive psychiatry, isoallopregnanolone is regarded as the archetype of an entirely new therapeutic strategy: instead of adding GABAergic tone with a sedative, it selectively subtracts the surplus tone contributed by a single endogenous steroid. Reviews of GABA-active steroids and their antagonists consistently position it as the reference GAMSA and cite it as validation that the 3alpha versus 3beta stereochemistry of pregnane steroids is a genuine molecular switch between agonism and antagonism (Backstrom 2022; Bixo 2018; Sundstrom-Poromaa 2023).

Its clinical reputation is more measured; the PMDD program generated encouraging but not unambiguous efficacy signals, and the compound remains investigational rather than approved. It is frequently discussed alongside its structural relatives allopregnanolone (brexanolone), zuranolone, and the orally active analogue golexanolone as part of the broader neurosteroid renaissance in psychiatry. It has essentially no presence as a consumer supplement and is not an ingredient people can purchase.